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Abstract
In prostate cancers, epidemiological data suggest a link between prostate inflammation and subsequent cancer de-
velopment, but proof for this concept in a tumor model is lacking. A constitutively active version of IκB kinase 2
(IKK2), which is activated by many inflammatory stimuli, was expressed specifically in the prostate epithelium. Con-
stitutive activation of the IKK2/nuclear factor κB axis was insufficient for prostate transformation. However, in com-
bination with heterozygous loss of phosphatase and tensin homolog, IKK2 activation led to an increase in tumor size,
formation of cribriform structures, and increase in fiber in the fibroblastic stroma. This phenotype was coupled with
persistent inflammation evoked by chemokine expression in the epithelium and stroma. The hyperplastic and dys-
plastic epithelia correlated with changes evoked by decreased androgen receptor activation. Conversely, inflamma-
tion correlated with stromal changes highlighted by loss of smooth muscle cells around prostate ducts. Despite
the loss of the smooth muscle barrier, tumors were rarely invasive in a C57BL/6 background. Data mining revealed
that smooth muscle markers are also downregulated in human prostate cancers, and loss of these markers in pri-
mary tumors is associated with subsequent metastasis. In conclusion, our data show that loss of smooth muscle
and invasiveness of the tumor are not coupled in our model, with inflammation leading to increased tumor size
and a dedifferentiated stroma.
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Introduction
Inflammation as a causal agent has been linked to approximately 20%
of human cancers [1]. The type and nature of inflammatory infiltrates
are different for different cancer types, and thus, a number of different
mechanisms for the tumor-promoting effect of inflammation have been
proposed [2]. In prostate cancer, a growing amount of evidence sug-
gests a link between chronic or persistent inflammation and tumor
development [3]. First, epidemiological data indicate that people diag-
nosed with chronic prostatitis have an increased risk of developing
prostate cancer at a later age. Moreover, people receiving long-term
treatment with nonsteroidal anti-inflammatory drugs have a reduced
risk of developing prostate cancer [4–6]. Second, histologic data imply
that certain lesions (sometimes referred to as prostate inflammatory
atrophy) are frequently found near prostate intraepithelial neoplasias
(PINs), precursor lesions of prostate cancer [7]. Third, treatment of
rodent prostates with bacteria induces prostatitis and hyperplastic and
dysplastic epithelial alterations [8,9]. Although all these data suggest
a link between prostatitis and tumor formation, the cause of prostate
inflammation in humans is largely unknown. However, many possible
causes for an inflammatory phenotype, such as bacterial or viral infec-
tions or production of inflammatory cytokines and chemokines, share
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common signaling pathways that are activated in the affected tissue.
All of the aforementioned stimuli activate the IκB kinase 2 (IKK2),
a key mediator between extracellular signaling and the transcription
factor NF-κB [10]. Although IKK2 has some other targets, its main
function is phosphorylation of IκB (inhibitors of κB) molecules, ren-
dering them subject for degradation and thus activating NF-κB. More-
over, IKK2 has been described as an oncogenic kinase; activated IKK2
correlates with poor clinical outcome in breast cancer patients, and the
enzyme targeting IKK2 for ubiquitination and degradation is lost or
mutated in different human cancers [11,12]. For the prostate, it is
interesting to note that the aforementioned relationship between long-
term drug treatment and reduced prostate cancer risk is more significant
for aspirin, which is also an IKK2 inhibitor.
In this work, we describe a novel genetic mouse model for inflam-
matory signaling in the prostate epithelium based on the expression of
a constitutively active version of the IκB kinase 2 (IKK2ca). Using the
Cre/LoxP system and the well-described Probasin-Cre mice [13], we
expressed IKK2ca in epithelial cells of the mouse prostate with or
without a monoallelic deletion of the tumor suppressor phosphatase
and tensin homolog (PTEN; monoallelic loxP-f lanked PTEN) in the
same cells. PTEN is a tumor suppressor frequently mutated or lost in
prostate cancer. In mouse models, PTEN deficiency in the epithelium
shows a dose-dependent transformation of prostate tissue, with low-
grade PIN late in mouse life in monoallelic deletions and lesions with
ability to form invasive and eventually metastasizing carcinomas in
full deletions [14–16]. We wanted to answer the questions whether
signaling through IKK2/NF-κB is sufficient to transform prostate tis-
sue and whether IKK2 activation in mild neoplastic lesions can ad-
vance tumor formation. We will refer to prostates carrying normal or
modified epithelia as wild-type, prostate epithelium (PE−)IKK2ca, PE−
PTEN+/−, or PE−PTEN+/−IKK2ca.
Materials and Methods
Mice
Probasin-Cre (PB-Cre4) mice were obtained from the National Can-
cer Institute – Frederick Mouse Repository. Mice with a floxed PTEN
allele [17] were a gift from Prof Tak Mak. R26StopFlIKK2ca mice were
generated by one of the authors (M.S.-S.) and were described previously
[18]. Mice were bred on a C57BL/6 background. Their housing and
euthanasia were in accordance with institutional guidelines.
RNA Extraction and Quantitative Polymerase Chain
Reaction Analysis
Harvested tissue was stored in RNA later, then homogenized using
a Polytron homogenizer, and purified on RNA binding columns ac-
cording to the manufacturer’s instructions (RNeasy [Qiagen, Hilden,
Germany] or Total RNA Kit [Peqlab, Erlangen, Germany]). Comple-
mentary DNA (cDNA) synthesis was performed using the RevertAid
H Minus First Strand cDNA Synthesis Kit (Fermentas, St. Leon-Rot,
Germany) and random hexamer primers. Quantitative polymerase
chain reaction (PCR) was done on a StepOne Plus Real-time PCR
Cycler (Applied Biosystems, Vienna, Austria). HPRT was used as nor-
malization gene. Primer sequences are listed in Table W1.
Microarray Experiment
Total RNA was extracted from lateral prostates of three animals
(12 months) with PTEN+/−IKK2ca/ca prostates and three age-matched
animals with PTEN+/− prostates using RNeasy (Qiagen). RNA quality
control, labeling, hybridization, and initial data analysis were done by an
Affymetrix service provider (KFB Regensburg, Regensburg, Germany).
Complete array data are stored in GEO (accession no. GSE26410).
For presentation in tables, log2 signals from the Robust Multichip Anal-
ysis were transformed into linear signals, and the mean expression fold
was calculated by dividing the average signal from the PE−PTEN+/−
IKK2ca/ca by the average signal from the PE−PTEN+/− group.
Explant Culture
Dissected prostate tissue was cut into pieces of 0.2 to 1 mm, placed on
collagenated tissue culture plates, and supplied with minimal amount of
epithelial growth medium containing 1% serum as described by Barclay
and Cramer [19]. After 24 hours, more media were added. After further
24 to 48 hours, cells began to grow out from the prostate tissue. Clean
epithelial or stromal cultures were obtained by removing the unwanted
cell type with a cell scraper or pipette tip. Cells were passaged using Accu-
tase (PAA, Pasching, Austria). For generation of cell lines, cells were pas-
saged until they survived crisis. Cell lines were treated in some experiments
with tumor necrosis factor (TNF; 20 ng/ml; Immunotools, Friesoythe,
Germany) or BMS-345541 (10 μM; Sigma, Schnelldorf, Germany).
Tissue Sectioning and Immunostaining
For paraffin sections, harvested tissue was fixed overnight in 4% para-
formaldehyde. Tissues were then dehydrated, embedded in paraffin in
small tissue blocks, cut (2-μm sections) using a Leica microtome (Leica
Microsystems, Vienna, Austria), and collected on SuperFrost Plus slides
(Thermo Scientific, Braunschweig, Germany). Antibody staining proce-
dure has been described [20]. Apoptosis was assessed using the TUNEL
method and the In SituCellDeathDetectionKit (Roche, Vienna, Austria).
For frozen sections, harvested tissue was directly frozen in isopentane/
liquid nitrogen and stored at −80°C until cutting. Staining was done
as described [20]. For biotinylated antibodies, sections were blocked
with Avidin/Biotin Blocking Kit (Vector Laboratories, Burlingame,
CA). Antibodies used are described in Table W2.
Histologic Assessment
Hematoxylin and eosin (H&E) staining from paraffin sections was
judged in a blind fashion by an expert pathologist (N.K.).
Microscopy and Image Analysis
Images were acquired on an Olympus AX470 microscope (Olympus,
Vienna, Austria) equipped with F-View II (grayscale) and ColorViewII
(color) digital cameras using the manufacturer’s software (CellP; Olym-
pus) and appropriate filter sets for fluorescence.
For the quantification of stromal elements, individual ducts (>5)
were randomly chosen on H&E staining of lateral prostates, and the
number of fibers between the gland and the neighboring gland was
counted. The average number of fibers was calculated for each pros-
tate tissue. The numbers given in the figures represent the arithmetic
average and SD over the individual values.
For the quantification of smooth muscle thickness versus CD11b
count, parameters were quantified using ImageJ (National Institutes of
Health, Bethesda, MD). The diameter of smooth muscle was quantified
using the anti-actin staining and the line selection of ImageJ. CD11b-
positive cells were counted within the duct and in the stroma closer to
the investigated duct than the neighboring one and were then normalized
to the area of the respective duct.
For quantification of Ki67- and TUNEL-positive cells, polymorpho-
nuclear inflammatory cells were excluded from the analysis.
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For quantification of androgen receptor (AR) nuclear/cytoplasmic
ratio, AR fluorescent staining was analyzed using elliptical regions
inside and just outside the nucleus and determining the mean gray
value of the regions in ImageJ. Nuclear regions were identified by over-
laying Hoechst staining.
Statistical Analysis
One-way analysis of variance was used to determine statistical signifi-
cance, where applicable. P < .05 was considered statistically significant.
Error bars in figures represent SEM.
Results
IKK2 Activity Is Insufficient to Transform Prostate Epithelium
Given the central role of IKK2 as a signal mediator from inflamma-
tory agents to transcription factors and its description as an oncogenic
kinase, we wanted to determine whether chronic IKK2 activity leads
to transformation of the prostate epithelium. On excision of the Stop
cassette in R26StopFlIKK2ca mice, transgene expression was con-
firmed by means of the Flag-tag of the IKK2 transgene (Figure 1A).
As expected, the expression was restricted to the epithelium. Dissection
of the different prostate lobes and expression analysis using quantita-
tive reverse transcription–polymerase chain reaction (RT-PCR) showed
that transgene expression was highest in the lateral prostate, followed
by the anterior and dorsal prostates, and was lowest in the ventral pros-
tate (Figure 1B). Down-regulation of IκBα, which is degraded after
phosphorylation by IKKs, indicated IKK2 activity (Figure 1C ). How-
ever, no histologic phenotype of the prostate tissue was noticed after
4 (n = 3), 8 (n = 4), or 12 (n = 10) months of age either in animals
expressing IKK2ca from a single allele or in animals expressing the
transgene from both alleles (Figure 1D). We conclude that constitu-
tively active IKK2 is insufficient to transform prostate tissue.
IKK2 Activity on PTEN+/− Background Increases Tumor
Size and Epithelial and Stromal Proliferation
Transgenic prostates with monoallelic deletion of the PTEN tumor
suppressor (PTEN+/−) in the epithelium develop low-grade PIN late
in mouse life (around 10-12 months). We wanted to know whether
IKK2 signaling could enhance this tumor development and alter either
tumor size or invasiveness. Expression of constitutively active IKK2 in
PTEN+/− prostate epithelium led to a clearly visible increase in prostate
size (Figure 2A, after 12 months). The difference was significant after
8 months and not seen at 4 months (not shown). PTEN+/− epithelium
expressing IKK2ca on both alleles (IKK2ca/ca) had all prostate lobes en-
larged at 8 months and older, whereas PE−PTEN+/−IKK2ca (expressing
IKK2ca from one allele) only showed enlarged lateral prostates, in line
with transgene expression being highest in the lateral lobe (Figure 2C ,
cf., Figure 1B). Histologic staining of these prostates showed normal,
smooth epithelium in prostates from wild-type littermates, whereas
most PE−PTEN+/− prostates had some hyperplasia and focal nuclear
abnormalities judged as murine PIN. PTEN+/− IKK2ca (or ca/ca) epi-
thelium was severely hyperplastic, often leading to cribriform structures,
Figure 1. IKK2 signaling is insufficient to transform prostate epithelium. (A) schematic drawing of the R26StopFlIKK2ca mouse line (loxP
sites: triangles) and anti-Flag staining. (B) Quantitative RT-PCR for the Flag-IKK2 transgene in different prostate lobes of IKK2ca/ca ex-
pressing mice (n = 4). (C) Immunostaining of frozen sections of wild-type or PE−IKK2ca/ca prostates with IκBα antibody. (D) H&E stain
from lateral prostate of IKK2ca/ca expressing mouse (12 months). Scale bars, 50 μm (A, D); 100 μm (C). Error bars, SEM. *P < .05.
AP indicates anterior prostate; DP, dorsal prostate; LP, lateral prostate; VP, ventral prostate.
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but had an equal incidence of nuclear atypia as PTEN+/− epithelium
(Figure 2B, upper panels). Moreover, PE−PTEN+/−IKK2ca(ca) prostates
showed a dramatic stromal response, indicated by dense and numerous
collagen fibers in comparison to the loose stroma with few fibers in
normal or PE−PTEN+/− prostates (Figure 2B, lower panels, quantified
in Figure 2D). This increase in tumor size was due to an increase in
proliferation of both epithelial and stromal cells, as indicated by more
Ki67-positive cells in epithelium and stroma, respectively (Figure 2, E
and F ). Apoptosis assessed by TUNEL stain was low and not signifi-
cantly changed in one of the genotypes (Figure W1).
Figure 2. IKK2 activity on PTEN+/− background increases tumor size and epithelial and stromal proliferation. (A) Steromicroscopical im-
ages of the structures surrounding the urethra (u), bladder (bl), and seminal vesicles (SV) from 12-month-old mice. The prostate lobes are
seen between the noted structures. (B) H&E stain of lateral prostates at 12 months, focusing on epithelium (upper panels) and stroma
(lower panels). The genotypes are according to labeling in A. (C) Quantification of dry prostate weight of lateral prostates at 12 months.
(D) Stromal fiber number in between epithelial ducts (see Materials and Methods) of 12-month-old lateral prostates. (E) Paraffin sections of
lateral prostates (12 months) stained for proliferation marker Ki67. Positive cells in the epithelium (arrowhead) and stroma (arrow) are seen.
Hoechst staining of the same sections (lower panels) are given to indicate tissue structure. (F) Quantification of Ki67-positive cells in the
epithelium and stroma for the indicated genotypes. Scale bars, 5 mm (A); 50 μm (B, E). Error bars, SEM. *P < .01.
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Persistent Inflammation in PE−PTEN+/− IKK2ca Prostates
The proliferative epithelium and stromal response were coupled
with signs of severe prostatitis in PE−PTEN+/− IKK2ca(ca) prostates.
Prostate tissue showed infiltration of granulocytes characterized by
their polymorphic nuclei and positive staining with the neutrophil
marker Lipocalin2 (Figure 3, A and B). The infiltrates were seen in
the stroma but also in the epithelium where they could be easily spotted
in the lumina of cribriform structures (Figure 3A). Wild-type tissue
and younger PE−PTEN+/− (4 months, n = 3; 8 months, n = 5) were
devoid of infiltrates, although with advanced age (>12 months), some
PE−PTEN+/− prostates also developed signs of prostatitis (analysis in
Figure 3C). Immunofluorescence analysis revealed positive staining of
infiltrates with the macrophage/monocyte antigen CD11b, the macro-
phage marker F4/80, and the neutrophil marker Gr-1 (Figure 3D).
Leukocytes positive for CD3e were also seen but were generally rare
(not shown). Control tissues from PE−PTEN+/−IKK2ca/ca mice did
not show any signs of inflammation, and noninflamed prostates did
not show positive immunoreactivity with immune cell marker anti-
bodies (Figure W2). We conclude that the prostate-specific expres-
sion of constitutively active IKK2 on a PE−PTEN+/− background
leads to severe persistent inflammation characterized by infiltration of
neutrophil granulocytes and macrophages.
Loss of Smooth Muscle but No Invasion in PE−PTEN+/−
IKK2ca(ca) Prostates
Because histologic staining of prostate tissue showed a dramatic
change in the stroma, we investigated the expression of various candi-
date genes known or thought to be expressed in the prostate stroma.
We found a dramatic down-regulation of smooth muscle cell markers,
smooth muscle myosin heavy chain (MYH11), and smooth muscle
Figure 3. Inflammation in PE−PTEN+/−IKK2ca transgenic prostates. (A) H&E staining of lateral prostates from 12-month-old mice. Arrow-
heads indicate polymorphonuclear granulocytes. (B) Staining for the neutrophil marker Lipocalin2 (12 months). (C) Analysis of prostatitis
seen in transgenic or wild-type prostates at 12 months. − indicates no prostatitis; +, focal prostatitis; ++, prostatitis in the major part of
the prostate gland. (D) Antibody staining of consecutive cryosections from dorsal prostates of PE−PTEN+/−IKK2ca/ca mice using marker
genes CD11b, F4/80, and Gr-1. Scale bars, 50 μm.
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actin (SMA) in PE−PTEN+/− IKK2ca prostates compared with wild-
type or PE−PTEN+/− (Figure 4A). This was confirmed by staining
lateral prostates with SMA antibody, demonstrating a complete loss of
smooth muscle cells around many prostatic ducts (Figure 4B). In many
tumor models, loss of smooth muscle around the stratified epithelium
is indicative of an invasive phenotype. Thus, we reinvestigated our
samples for invasive carcinoma formation. Histologically, the larger tu-
mors in PE−PTEN+/− IKK2ca(ca) prostates were still well confined,
with no signs of “dripping-off” of smaller epithelial structures or even
invasion into the neighboring tissue (Figure 4C ). Another indication of
invasiveness is loss of basal cells in the epithelium. Costaining of smooth
muscle marker and the basal cell marker p63 confirmed that, even in
glands with complete loss of smooth muscle, basal cell expression is
maintained (Figure 4D).
Rarely observed carcinomas formed unilaterally in PE−PTEN+/−
IKK2ca(ca) prostates, suggestive of a further mutation or transforming
event. We examined such a carcinoma and did not find overexpression
of factors known to be associated with invasiveness such as Spink genes,
Ets transcription factors, or myc, indicating that a different set of genes
was responsible for invasiveness (Figure W3).
Taken together, these data show that PE− PTEN+/− IKK2ca pros-
tates exhibit a profound change in the stroma highlighted by a loss of
smooth muscle around the stratified epithelium but without regular
formation of invasive structures.
Expression Profiling Details the Inflammatory
Tumor Phenotype
To gain insight into the molecular mechanism of inflammation and
tumor development in the transgenic prostates, we performed micro-
array analysis on PE−PTEN+/−IKK2ca/ca or PE−PTEN+/− lateral
prostates. Overexpressed (PE−PTEN+/− IKK2ca/ca vs PE−PTEN+/−)
or downregulated genes were determined and grouped according to
function (Table 1; the 100most overexpressed and downregulated genes
are listed in Tables W3 and W4). We then confirmed misexpression
of many of these genes by quantitative RT-PCR or immunoblot analy-
sis (Figure 5). Consistent with the absence of a histologic phenotype,
PE−IKK2ca prostates did not overexpress these candidate genes (Fig-
ure W4). One group of genes overexpressed in PE−PTEN+/−IKK2ca/ca
prostates constituted chemokines such as CXCL5, CXCL15, CCL3,
CXCL10, and CXCL2. These chemokines are known to attract im-
mune cells, particularly neutrophil granulocytes and monocytes/macro-
phages, the cells found in the inflamed tissue (Figure 3). Consistently,
another group of genes comprised genes found predominantly or ex-
clusively in granulocytes or macrophages. Inflammatory cytokines,
Figure 4. Loss of smooth muscle cells, but no invasion in PE−PTEN+/− IKK2ca(ca) prostates. (A) Quantitative RT-PCR for smooth
muscle cell markers from lateral prostates (12 months), n = 6 per group. (B) Colored immunofluorescence staining for smooth muscle
actin (SM Actin) and Hoechst counterstain in dorsal prostates (12 months). (C) H&E staining of paraffin sections from PE−PTEN+/−
IKK2ca/ca prostates. (D) Costaining for SMA and basal cell marker p63 in paraffin-embedded sections from PE−PTEN+/− IKK2ca/ca
prostates (12 months). Scale bars, 50 μm (B, D); 100 μm (C). Error bars, SEM. *P < .05, **P < .01.
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particularly TNF but also IL-1b, were also overexpressed in the tissues
exhibiting prostatitis. These cytokines are known target genes of the
transcription factor NF-κB. Other classic NF-κB targets identified in-
cluded IκB proteins and the adhesion molecule ICAM1. Of note, we
also identified the secreted frizzle-related proteins 1 and 4 (SFRP1 and
4) as overexpressed in PE−PTEN+/−IKK2ca/ca. SFRP1 has been de-
scribed as a candidate gene expressed by the stroma to modulate the
epithelium in prostate cancer progression [21]. This shows that the acti-
vated stroma in our intraepithelial tumors bears resemblance to human
prostate cancer stroma.
In line with the analysis of the changes in stroma (Figure 4), some
of the most downregulated genes were identified to be smooth muscle
cell markers myosin heavy chain 11 (MYH11) and calponin 1. More-
over, we found genes associated with prostate tumor progression to
be changed: First, the tumor suppressor Nkx3-1 was downregulated.
Nkx3-1 is known to be frequently lost in human prostate cancer, and
genetic ablation of the gene in the mouse resulted in hyperplasia and
PIN formation [22]. This correlates with our finding of increased
tumor proliferation in PE−PTEN+/−IKK2ca and is consistent with
findings in a model of bacterial prostatitis [23]. Second, a group of
serine protease inhibitors (Spink genes) was downregulated. Spink3,
which topped the list of downregulated genes, is the murine homolog
of human Spink1, identified as an upregulated gene in a subset of pros-
tate cancers negative for translocation of Ets transcription factors. In
these cancers, Spink1 overexpression is associated with invasiveness
[24]. This correlates with our finding that the larger tumors in PE−
PTEN+/−IKK2ca(ca) prostates failed to become invasive carcinomas.
Furthermore, the consistent down-regulation of many Spink family
members suggests a common regulatory mechanism for Spink genes.
The loss of smooth muscle was also analyzed in human prostate
tumors. We used Oncomine (Compendia Bioscience), a database
comprising a number of microarray data sets from human tumors, to
determine regulation of the markers found in our transgenic mouse
lines. We found a number of data sets with down-regulation of smooth
muscle cell markers in carcinomas versus normal prostate indicating
loss of smooth muscle as an event in carcinoma formation (one data
set [25] is shown in Figure 5C). This confirms that tumors in the in-
flamed mouse prostate tissue show advanced tumor formation and
share similarities with human cancers.
Epithelial and Stromal Cells Produce
Inflammatory Chemokines
The inflammatory phenotype in PE−PTEN+/−IKK2ca/ca prostates
is somehow evoked by the transgenically modified epithelium. We
wanted to confirm that inflammatory chemokines or cytokines over-
expressed in the whole prostate tissue samples are indeed produced by
the transgenic epithelium. To this end, we established cell lines from
transgenic mice and wild-type littermates by explant cultures (Fig-
ure 6A). Epithelial lines from PE−PTEN+/−IKKca/ca and wild-type
prostates expressed E-cadherin and luminal cell marker cytokeratin
18, whereas stromal lines expressed collagen I (Figure W5). Interest-
ingly, a wild-type epithelial (wt) and one transgenic epithelial line
(epII) expressed basal cytokeratin 14, whereas another transgenic epi-
thelial line (epI) did not. We conclude that the lines wt and epII show
a more intermediate and that the line epI shows a more luminal pheno-
type based on cytokeratin expression. The Flag-IKK2 transgene was
confirmed to be expressed in transgenic epithelium only. SFRP1, the
reported stroma-to-epithelial modulator, was expressed in the stroma
(Figure W5B). With respect to chemokine expression, we could show
that most of the chemokines are indeed overexpressed in the transgenic
epithelium, and their expression was higher in the luminal line com-
pared with the intermediate line (Figure 6). CXCL5 and CXCL15
(Figure 6B) are strongly overexpressed in the epithelial lines, with mod-
erate overexpression of CXCL10 and CXCL2 (not shown). Interest-
ingly, the adhesion molecule ICAM1 is also strongly overexpressed in
the epithelium (Figure 6B), and ICAM1 has been described as a recep-
tor for neutrophil granulocytes [26]. This correlates with the finding
that these inflammatory cells are located within the epithelium of PE−
PTEN+/−IKK2ca/ca prostates (Figure 3). Overexpression of ICAM1
in the epithelium was confirmed by tissue section staining, indicating
that it was no cell culture artifact (Figure 6C). Moreover, TNF was ex-
pressed in the transgenic epithelium. We tested the hypothesis that the
stroma activated by cytokines from the epithelium could also express
immune cell-attracting chemokines. Indeed, TNF treatment of stromal
cultures induced messenger RNA (mRNA) ofCXCL2 (Figure 6D) and,
to a lesser extent, CXCL10 (Figure W5) but not CXCL5 or CXCL15.
Furthermore, treatment of the epI cell line with the IKK/NF-κB in-
hibitor BMS-345541 decreased cytokine and chemokine expression,
confirming that the transgenic activation of the IKK2/NF-κB axis is
responsible for the overexpression of these molecules (Figure 6E).
Taken together, these data indicate that the transgenic PTEN+/−
IKK2ca/ca epithelium can attract inflammatory cells by direct and/or
indirect production of chemokines.
Table 1. Selected Genes from the 100 Most Overexpressed or Underexpressed Genes from
Microarray Analysis.
Gene (Abbreviation) Full Name Fold Expression
Upregulated genes
Immune cell associated
Cd14 Cd14 antigen 6.97
Csf3r Colony-stimulating factor 3 receptor (granulocyte) 4.83
Mpeg1 Macrophage expressed gene 1 3.64
Chemokines and receptors
Cxcl5 Chemokine (C-X-C motif ) ligand 5 11.68
Cxcl15 Chemokine (C-X-C motif ) ligand 15 7.22
Cxcl10 Chemokine (C-X-C motif ) ligand 10 5.35
Cxcl2 Chemokine (C-X-C motif ) ligand 2 4.10
Ccl3 Chemokine (C-C motif ) ligand 3 5.11
Cxcr4 Chemokine (C-X-C motif ) receptor 4 3.60
Cytokines and receptors
Tnf Tumor necrosis factor 4.28
Il1f9 Interleukin 1 family, member 9 3.85
Il1b Interleukin 1β 3.62
Il8rb Interleukin 8 receptor, β 5.15
NF-κB target genes
C3 Complement component 3
Nfkbia IκBα 3.52
Nfkbie IκBɛ 4.38
Icam1 Intercellular adhesion molecule 1 6.94
Other
Sfrp4 Secreted frizzle-related protein 4 7.76
Sfrp1 Secreted frizzle-related protein 1 3.54
Downregulated genes
Smooth muscle cell markers
Myh11 Myosin, heavy polypeptide 11, smooth muscle 0.12
Cnn1 Calponin 1 0.18
Spink genes
Spink3 Serine peptidase inhibitor, Kazal type 3 0.005
Spink5 Serine peptidase inhibitor, Kazal type 5 0.03
Spink11 Serine peptidase inhibitor, Kazal type 11 0.16
Spink8 Serine peptidase inhibitor, Kazal type 8 0.20
Prostate-specific genes
Pbsn Probasin 0.06
Tgm4 Transglutaminase 4 (prostate) 0.07
Nkx3-1 NK-3 transcription factor, locus 1 (Drosophila) 0.13
RNA was extracted from 12-month-old PE−PTEN+/−IKK2ca/ca or PE−PTEN+/− lateral prostates.
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Loss of Smooth Muscle Correlates with Prostate Inflammation
We wanted to establish a correlation between the inflammatory
phenotype and loss of smooth muscle. To this end, we stained PE−
PTEN+/− IKK2ca/ca dorsal prostates where smooth muscle was only
partially lost, with both smooth muscle (SMA) and inflammatory cell
marker (CD11b). In prostatic ducts with intense inflammatory cell
infiltration, the smooth muscle was lost completely (Figure 7A, arrow),
whereas in ducts with little or no signs of inflammation, the smooth
muscle was maintained or partially intact (Figure 7A, arrowheads).
Quantification over a number of prostatic ducts established a correla-
tion between smooth muscle thickness and inflammatory cell infil-
tration (Figure 7B).
Reduced Epithelial Androgen Receptor Activation in
Transgenic Prostates
Down-regulation of Nkx3-1, an androgen-responsive gene, in PE−
PTEN+/−IKK2ca prostates suggested reduced AR activation in the
epithelium. Staining of wild-type and transgenic prostates showed less
nuclear (activated) AR in the hyperplastic tissues (Figure 8, A and B).
A decrease in AR activity was also indicated by down-regulation of
other androgen-responsive genes such as Probasin (Figure 8C). These
data suggest that decreased AR activity could be responsible for the
hyperplastic epithelium by downregulating Nkx3-1.
Discussion
In this study, we sought to elucidate the effects of inflammation and
inflammatory signaling on early events of prostate tumorigenesis. The
main reason for this is that epidemiological data suggest a role for
inflammation in tumor initiation or early progression. Thus, we ana-
lyzed IKK2 signaling on a wild-type and PE−PTEN+/−, but not PE−
PTEN−/− background, because the latter has been described to result
in full carcinoma formation over time. The effect of NF-κB signaling
on late-stage prostate tumorigenesis has been addressed by other groups
and determined a role for NF-κB in promoting androgen-independent
growth [27].
Inflammatory signaling through constitutive activation of the IKK2
axis in normal prostate epithelium is insufficient to transform pros-
tate tissue. This is interesting because IKK2 has been shown to be
an oncogenic kinase and activation on a PE−PTEN+/− background
shows a clear additional phenotype. One possible reason for this lack
of phenotype may be that IKK2/NF-κB transcription factors can acti-
vate promoters in proliferating epithelium that they cannot activate in
Figure 5. Confirmation of gene expression changes in transgenic prostates. (A, B) Quantitative RT-PCR experiments on samples from PE−
PTEN+/−IKK2ca/ca prostates (group 1), PE−PTEN+/− prostates (group 2), and wild-type littermate controls (group 3) (n = 6 per
group, extracted from 12-month-old tissues). (B) Immunoblot for Nkx3-1 and SFRP-1 (right panel). (C) Data mining of normal prostate
versus human prostate cancer. The data set of Vanaja et al. was queried by use of Oncomine, and the expression data were transformed
to the linear expression signal plotted in the bar graph. Error bars, SEM. *P < .05; **P < .01; ***P < .001.
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quiescent epithelium such as the prostate epithelium. Consistent with
this, some NF-κB dependent promoters were not activated in PE−
IKK2ca prostates compared with wild-type prostates. Moreover, we
have found a clear phenotype- and NF-κB–dependent gene expression
when expressing the same transgene from the same strain in keratino-
cytes of the skin, a proliferating epithelium (Birbach et al., unpublished
observations). The Probasin-Cre strain used in our study excises loxP-
flanked sequences only in the adult, quiescent epithelium. Excision
efficiency increases with age, in line with the age-dependent phenotype
in PE−PTEN+/−IKK2ca(ca) [28].
Our experiments on PE−PTEN+/−IKK2ca(ca) indicate that some
of the more upregulated genes in prostate epithelium in response to
NF-κB are inflammatory cytokines and chemokines. This is in agree-
ment with chemokine production from other epithelia in response
to NF-κB [29]. The chemokines from the epithelium and cytokine-
activated stroma (a finding consistent with data from human stromal
cells [30]) are likely attractors for the infiltrating inflammatory cells.
The inflammation evoked phenotype in both the epithelium and the
stroma: the severe hyperplasia in dysplastic epithelial lesions was due
to the increased proliferation, not apoptosis, consistent with expression
data indicating no major change in regulators of apoptosis, but down-
regulation of Nkx3-1, a guardian of epithelial proliferation. Nkx3-1
loss in the epithelium is necessary for tumor initiation in tumor models
and human cancer and could have a similar function in our model [31].
Reduced AR activation is a likely contributor to the decrease in Nkx3-1.
In this context, the relationship between NF-κB and AR activity is
complex, with different outcomes in in vitro experiments by different
groups [32,33]. In our model, we hypothesize that the modified stromal-
to-epithelial signaling could play a role in modifying AR activity.
In the stroma, increases in fibroblasts and collagen fibers were remi-
niscent of activated prostate cancer stroma, and expression data showed
some upregulated genes known for their expression in cancer-associated
fibroblasts. Loss of smooth muscle and concomitant increase of stromal
fibroblasts suggest that the smooth muscle is lost by a dedifferentiation
to fibroblastic cells. Various factors have been described to be involved
in smooth muscle dedifferentiation, including inflammatory mediators
[34,35]. Prostate smooth muscle cells can be partially dedifferentiated
by LPS treatment, and partial vascular smooth muscle dedifferentiation
by IL-1b can be enhanced by PGE-2. Along the same lines, we have
observed a small decrease in smooth muscle markers by treating pros-
tate stroma with TNF (not shown). Although neither of these experi-
ments (during a time span of hours to days) result in complete loss of
smooth muscle identity, it is conceivable that persistent inflammation for
months and possible additive effects of different inflammatory mediators
can lead to complete dedifferentiation.
Figure 6. Inflammatory cytokines and chemokines are expressed in
cultured epithelial and stromal cells. (A) Bright-field images from cell
cultures of prostate epithelial cells from nontransgenic prostates (wt)
or PE− PTEN+/− IKK2ca/ca prostates (epI, epII) and from cultures
of prostate stromal cells from PE−PTEN+/− IKK2ca/ca prostates
(str). (B) Quantitative RT-PCR data (n = 3 per group). (C) Immuno-
staining for ICAM1 in frozen sections of dorsal prostates (12 months)
of the indicated genotypes. (D) Chemokine CXCL2 mRNA was deter-
mined in cultured stromal cells with or without TNF treatment for
24 or 48 hours (ctrl: untreated control). (E) mRNA was determined
in epI epithelial line treated with mock control or BMS-345541 for
72 hours. Scale bars, 50 μm. Error bars, SEM. *P < .05; **P < .01.
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Figure 7. Correlation of inflammatory cell infiltration and smooth muscle thickness. (A) Cryosections from 11-month-old PTEN+/−IKK2ca/ca
dorsal prostate were stained as indicated. Arrow indicates duct with loss of smooth muscle and infiltration of inflammatory cells. Arrow-
heads indicate ducts still surrounded by smooth muscle and less infiltration. (B) Quantification of dorsal prostate ducts (8-12 months). Scale
bars, 100 μm.
Figure 8. Reduced epithelial AR activation in PE−PTEN+/−IKK2ca/ca. (A) Paraffin sections of wild-type and transgenic tissue (anterior pros-
tate, 12 months) stained for AR with Hoechst counterstain. (B) Quantification for wild-type and transgenic tissues (n = 4 each). (C) Quanti-
tative PCR of androgen-responsive gene Probasin (n = 6 per group). Scale bars, 50 μm. **P < .01; *P < .05.
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Although the smooth muscle around the prostatic ducts was lost,
most tumors were not invasive by histologic or expression param-
eters. We laid emphasis on maintaining our mouse colony on a strict
C57BL/6 background, known as a strain with low tumor susceptibility
[36]. It is well possible that more carcinomas, especially microinvasive
structures, develop on a different inbred or mixed background; how-
ever, by using this approach, we were able to clearly distinguish the
effects mediated by the inflammatory phenotype from the secondary
events dependent on another genetic or epigenetic alteration in the
tumor. Along these lines, tumor models with partial loss of Nkx3-1
on a PE−PTEN+/− background have been shown to be more fre-
quently invasive than the tumors in our study but were bred on a mixed
background [37].
Loss of smooth muscle has been used as a hallmark for carci-
noma formation in mouse prostate tumor models [16,38]. Models
of epithelial-stromal interactions have proposed smooth muscle in-
tegrity to be necessary to control epithelial proliferation and dysplasia
[39,40]. Moreover, human prostate carcinoma is associated with down-
regulation of smooth muscle markers. Our data from the inflammatory
model show that loss of smooth muscle is not sufficient for the tumor
to become invasive but that the two events can be uncoupled.
One model of prostate carcinogenesis based on genetic analysis
and mouse models of prostate tumors suggests that a distinct step as-
sociated with the overexpression of either Ets transcription factors,
Spink1 gene, or other, yet unidentified genes must be taken to induce
invasion through the basement membrane and carcinoma formation
[24,41]. This is in agreement with our expression data from intra-
epithelial tumors of inflamed prostates with either unchanged (Ets fac-
tors) or even downregulated (Spink genes) invasion-associated genes.
In summary, as a genetic model, our model has advantages over
bacterially induced models of inflammatory tumorigenesis. It is a
reproducible model based on well-defined Cre-mediated deletion and
dissects effects mediated by inflammation and genetic lesions. Inflamed
prostates not only show enlarged tumor burden due to increased pro-
liferation but also exhibit a clear change in stromal mass and compo-
sition. On a well-defined background, the model demonstrates what
inflammation does by its own and what is due to genetic background
or further genetic or epigenetic alterations in the tumor. Invasion,
although rarely seen in our model, will be present in inflammatory
tumors but is not a direct consequence of inflammation in our model.
Loss of smooth muscle, an indicator of tumor progression, is seen in
inflammatory lesions and correlates with inflammation. Interestingly,
genetic data have revealed that loss of smooth muscle markers in pri-
mary tumors is part of a tumor signature predicting subsequent metas-
tasis and poor clinical outcome [42]. Thus, the inflammatory tumors
in our model, although not invasive without a subsequent transforming
step, may be more dangerous in the long run when acquiring additional
mutations to become carcinomas.
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Table W1. List of Oligonucleotides Used for Quantitative PCR Analysis.
Gene (Symbol) or Amplicon Primer Sequences (Sense and Antisense, 5′ → 3′)
CXCL2 GCGCCCAGACAGAAGTCATAG
AGCCTTGCCTTTGTTCAGTATC
CXCL5 GAAAGCTAAGCGGAATGCAC
GGGACAATGGTTTCCCTTTT
CXCL10 GCTCCTGCATCAGCACCAGC
CTTGAACGACGACGACTTTGG
CXCL15 CCA TGG GTG AAG GCT ACT GT
TCT CAG GTC TCC CAA ATG AAA
Cytokeratin18 CAGCCAGCGTCTATGCAGG
CTTTCTCGGTCTGGATTCCAC
ICAM1 TGC GTT TTG GAG CTA GCG GAC CA
CGA GGA CCA TAC AGC ACG TGC AG
TNF TAGCCAGGAGGGAGAACAGA
TTTTCTGGAGGGAGATGTGG
E-Cadherin AAGTGACCGATGATGATGCC
CTTCTCTGTCCATCTCAGCG
Collagen1 CAC CCT CAA GAG CCT GAG TC
GTT CGG GCT GAT GTA CCA GT
Flag-IKK2 GAC TAC AAG GAC GAC GAT GAC AAG
GGT TCA GCC TTC TCA TGA TCT GG
SFRP1 CAACGTGGGCTACAAGAAGAT
GGCCAGTAGAAGCCGAAGAAC
SFRP4 AGAAGGTCCATACAGTGGGAAG
GTTACTGCGACTGGTGCGA
Nkx3-1 ATGCTTAGGGTAGCGGAGC
TGCGGATTGCCTGAGTGTC
Spink3 ATG AAG GTG GCT GTC ATC TTT C
TCA GCA AGG CCC ACC TTT TCG
Smooth muscle actin GTCCCAGACATCAGGGAGTAA
TCGGATACTTCAGCGTCAGGA
Probasin AAGGCTCACCATTGAGAACCT
CAGTTGGCACTTAGTCCCTTTC
MYH11 AAGCTGCGGCTAGAGGTCA
CCCTCCCTTTGATGGCTGAG
HPRT CAA ATC AAA AGT CTG GGG ACG C
GCT TGC TGG TGA AAA GGA CCT C
Table W2. List of Antibodies Used in This Study.
Antibody/Antigen Source/Catalog No. (or Equivalent) Use/Dilution
CD3e eBioscience/13-0031 IF-F/1:200
F4/80 eBioscience/13-4801 IF-F/1:200
CD11b eBioscience/13-0112 IF-F/1:200
Gr-1 eBioscience/13-5931 IF-F/1:200
Ki67 Neomarkers/RM-9106-S1 IF-P/1:200
Lipocalin2 Santa Cruz/sc-18698 IHC-P/1:200
Nkx3-1 Santa Cruz/sc-15022 IB/1:400
Smooth muscle actin Sigma/C6198 IF-P/1:400
IF-F/1:400
P63 Santa Cruz/sc-56188 IF-P/1:100
Cytokeratin14 Prof E.B. Lane
(University of Dundee)
IF-cells/1:10
Androgen receptor Santa Cruz/sc-815 IF-P/1:100
β-Tubulin Santa Cruz/sc-9104 IB/1:400
IκBα Santa Cruz/sc-371 IB/1:1000, IF-F/1:100
ICAM1 eBioscience/14-0541 IF-F/1:100
A555 goat antirabbit Invitrogen/A-21428 IF-P, IF-F/1:2000
Biotin antirabbit Vector Laboratories/BA-1000 IHC-P/1:400
Biotin antigoat Vector Laboratories/BA-9500 IHC-P/1:400
Biotin antimouse Vector Laboratories/BA-9200 IHC-P/1:400
Streptavidin, Alexa Fluor
555 conjugate
Invitrogen/S32355 IF-F/1:500
F indicates frozen sections; IB, immunoblot; IF, immunofluorescence; IHC, immunohistochemistry;
P, paraffin sections.
Figure W1. TUNEL stain indicating no change in apoptosis in transgenic versus wild-type prostases. (A) TUNEL staining (see Materials
and Methods) was performed on paraffin sections from prostates of the indicated genotypes. Hoechst staining is given to indicate
tissue architecture and cell density. (B) Quantification of TUNEL-positive cells in lateral cells in the lateral prostates of the indicated
genotypes (n = 4 per group). Error bars, SEM. No statistical significance was reached in the analysis of variance.
Figure W2. Normal histologic finding of nonprostate tissues from PE−PTEN+/− IKK2ca/ca mice (A-F) and lack of immunoreactivity in
PE−PTEN+/− lateral prostates (G). H&E stains are shown for liver (A), lung (B), kidney (C), muscle tissue surrounding the urethra (D),
testis (E), and lymph node (F). Scale bars, 100 μm. (G) Antibody staining in PE−PTEN+/− lateral prostates. Scale bars, 50 μm.
Figure W3. Carcinoma formation in a PTEN+/−IKK2ca/ca lateral prostate (12 months). (A) H&E stain of the tumor itself (left) and adjacent
to the stroma (right). (B) Quantitative PCR data of carcinoma (n = 1) compared with PE−PTEN+/−IKK2ca/ca prostate (n = 3) or wild-type
prostate (n = 3). Scale bars, 50 μm.
Table W3. The 100 Most Overexpressed Genes in the Microarray Study Comparing PE−PTEN+/−
IKK2ca/ca to PE−PTEN+/−.
Gene Symbol Full Name Fold Expression
Msln Mesothelin 33.12
Ly6d Lymphocyte antigen 6 complex, locus D 13.64
Gabrp γ-Aminobutyric acid (GABA) A receptor, pi 13.16
Hp Haptoglobin 11.96
Clca2 Chloride channel calcium activated 2 11.78
Cxcl5 Chemokine (C-X-C motif) ligand 5 11.68
Olfm4 Olfactomedin 4 9.95
Egln3 EGL nine homolog 3 (C. elegans) 8.26
Slco1a5 Solute carrier organic anion transporter family, member 1a5 7.98
Sfrp4 Secreted frizzle-related protein 4 7.76
AW112010 Expressed sequence AW112010 7.61
Sftpd Surfactant associated protein D 7.26
Gdpd3 Glycerophosphodiester phosphodiesterase domain containing 3 7.23
Cxcl15 Chemokine (C-X-C motif) ligand 15 7.22
Ccdc129 Coiled-coil domain containing 129 7.00
Cd14 CD14 antigen 6.97
Icam1 Intercellular adhesion molecule 1 6.94
Tnfsf10 Tumor necrosis factor (ligand) superfamily, member 10 6.90
Car13 Carbonic anhydrase 13 6.90
Muc20 Mucin 20 6.78
Ctla2a Cytotoxic T-lymphocyte–associated protein 2α 6.66
Atp6v1b1 ATPase, H+ transporting, lysosomal V1 subunit B1 6.48
Aspa Aspartoacylase 6.42
C3 Complement component 3 6.07
Ltbp2 Latent transforming growth factor β binding protein 2 5.98
S100a8 S100 calcium binding protein A8 (calgranulin A) 5.74
Car2 Carbonic anhydrase 2 5.57
Cxcl10 Chemokine (C-X-C motif) ligand 10 5.35
Clic6 Chloride intracellular channel 6 5.28
Clip4 CAP-GLY domain containing linker protein family, member 4 5.21
Vsig1 V-set and immunoglobulin domain containing 1 5.20
Wfdc2 WAP four-disulfide core domain 2 5.18
Il8rb Interleukin 8 receptor, β 5.15
Ccl3 Chemokine (C-C motif) ligand 3 5.11
Ttc9 Tetratricopeptide repeat domain 9 5.05
Cyba Cytochrome b-245, α polypeptide 5.01
Clec4d C-type lectin domain family 4, member d 4.94
Cp Ceruloplasmin 4.89
Tnip3 TNFAIP3 interacting protein 3 4.84
Csf3r Colony stimulating factor 3 receptor (granulocyte) 4.83
Mmp3 Matrix metallopeptidase 3 4.81
Slfn4 Schlafen 4 4.75
Sestd1 SEC14 and spectrin domains 1 4.71
Gm7609 Predicted gene 7609 4.69
Cpxm1 Carboxypeptidase X 1 (M14 family) 4.65
Padi4 Peptidyl arginine deiminase, type IV 4.64
Itgb6 Integrin β6 4.63
Srgn Serglycin 4.59
Gm7609 Predicted gene 7609 4.58
Cd200r3 CD200 receptor 3 4.56
Clec4n C-type lectin domain family 4, member n 4.52
H2-Q6 Histocompatibility 2, Q region locus 6 4.49
Table W3. (continued )
Gene Symbol Full Name Fold Expression
Csprs Component of Sp100-rs 4.39
Nfkbie Nuclear factor of κ light polypeptide gene enhancer in B-cells
inhibitor, epsilon
4.38
Mgat3 Mannoside acetylglucosaminyltransferase 3 4.32
Clca1 Chloride channel calcium activated 1 4.29
Ces3 Carboxylesterase 3 4.29
Car8 Carbonic anhydrase 8 4.29
Tnf Tumor necrosis factor 4.28
Csprs Component of Sp100-rs 4.26
Wbscr17 Williams-Beuren syndrome chromosome region 17 homolog
(human)
4.18
Gpnmb Glycoprotein (transmembrane) nmb 4.17
Steap4 STEAP family member 4 4.13
Slc39a4 Solute carrier family 39 (zinc transporter), member 4 4.12
Cxcl2 Chemokine (C-X-C motif) ligand 2 4.10
Pglyrp1 Peptidoglycan recognition protein 1 4.04
Dram1 DNA-damage regulated autophagy modulator 1 3.97
Grid2 Glutamate receptor, ionotropic, delta 2 3.94
Atp6v0d2 ATPase, H+ transporting, lysosomal V0 subunit D2 3.90
Itga2 Integrin α2 3.85
Il1f 9 Interleukin 1 family, member 9 3.85
Capsl Calcyphosine-like 3.84
Pmepa1 Prostate transmembrane protein, androgen induced 1 3.80
Clec5a C-type lectin domain family 5, member a 3.78
Dclk1 Doublecortin-like kinase 1 3.73
S100a9 S100 calcium binding protein A9 (calgranulin B) 3.71
Gp49a Glycoprotein 49 A 3.69
Ly6k Lymphocyte antigen 6 complex, locus K 3.65
Mpeg1 Macrophage expressed gene 1 3.64
Il1b Interleukin 1β 3.62
Cxcr4 Chemokine (C-X-C motif) receptor 4 3.60
Eya2 Eyes absent 2 homolog (Drosophila) 3.59
Tyrobp TYRO protein tyrosine kinase binding protein 3.59
Pdgfrl Platelet-derived growth factor receptor-like 3.58
Sfrp1 Secreted frizzle-related protein 1 3.54
Casp1 Caspase 1 3.54
Gda Guanine deaminase 3.54
Nfkbia Nuclear factor of κ light polypeptide gene enhancer in B-cells
inhibitor, α
3.52
Gsdmc2 Gasdermin C2 3.49
Nedd9 Neural precursor cell expressed, developmentally downregulated
gene 9
3.49
Frzb Frizzle-related protein 3.49
Arl14 ADP-ribosylation factor-like 14 3.49
Gm7609 Predicted gene 7609 3.47
Krt7 Keratin 7 3.47
Ubd Ubiquitin D 3.45
Fcrls Fc receptor-like S, scavenger receptor 3.45
Mmp12 Matrix metallopeptidase 12 3.45
Serpinb11 Serine (or cysteine) peptidase inhibitor, clade B (ovalbumin),
member 11
3.44
Tgtp T-cell–specific GTPase 3.43
Lyz2 Lysozyme 2 3.38
Table W4. The 100Most Downregulated Genes in the Microarray Study Comparing PE−PTEN+/−
IKK2ca/ca to PE−PTEN+/−.
Gene Symbol Full Name Fold Expression
Spink3 Serine peptidase inhibitor, Kazal type 3 0.00
Sbp Spermine binding protein 0.01
Wfdc3 WAP four-disulfide core domain 3 0.02
Pnliprp1 Pancreatic lipase-related protein 1 0.02
Spink5 Serine peptidase inhibitor, Kazal type 5 0.03
4930408F14Rik RIKEN cDNA 4930408F14 gene 0.04
4930408F14Rik RIKEN cDNA 4930408F14 gene 0.04
4930408F14Rik RIKEN cDNA 4930408F14 gene 0.04
Syt10 Synaptotagmin X 0.04
4930408F14Rik RIKEN cDNA 4930408F14 gene 0.05
Abo ABO blood group (transferase A, α 1-3-N -
acetylgalactosaminyltransferase, transferase B,
α 1-3-galactosyltransferase)
0.05
Eapa2 Experimental autoimmune prostatitis antigen 2 0.05
Pbsn Probasin 0.06
G6pc2 Glucose-6-phosphatase, catalytic, 2 0.06
9530002B09Rik RIKEN cDNA 9530002B09 gene 0.06
Derl3 Der1-like domain family, member 3 0.06
Azgp1 α-2-Glycoprotein 1, zinc 0.07
Atp12a ATPase, H+/K+ transporting, nongastric, α polypeptide 0.07
4930408F14Rik RIKEN cDNA 4930408F14 gene 0.07
Defb10 Defensin β10 0.07
Tgm4 Transglutaminase 4 (prostate) 0.07
4930408F14Rik RIKEN cDNA 4930408F14 gene 0.07
D030018L15Rik Nuclear receptor coactivator 2 pseudogene 0.07
4930408F14Rik RIKEN cDNA 4930408F14 gene 0.08
Pcp4 Purkinje cell protein 4 0.08
4930408F14Rik RIKEN cDNA 4930408F14 gene 0.08
Gm5615 Predicted gene 5615 0.08
Defb1 Defensin β1 0.09
Ceacam2 Carcinoembryonic antigen–related cell adhesion molecule 2 0.09
Hmgcs2 3-Hydroxy-3-methylglutaryl-coenzyme A synthase 2 0.09
Htr3a 5-Hydroxytryptamine (serotonin) receptor 3A 0.09
Atp6v1c2 ATPase, H+ transporting, lysosomal V1 subunit C2 0.09
Cyp3a57 Cytochrome P450, family 3, subfamily a, polypeptide 57 0.10
Agtr1a Angiotensin II receptor, type 1a 0.10
Mme Membrane metalloendopeptidase 0.10
Prom2 Prominin 2 0.10
Aass Aminoadipate-semialdehyde synthase 0.11
Slc9a2 Solute carrier family 9 (sodium/hydrogen exchanger),
member 2
0.11
Epha3 Eph receptor A3 0.11
Smgc Submandibular gland protein C 0.11
Decaf12l1 DDB1 and CUL4 associated factor 12-like 1 0.11
Myh11 Myosin, heavy polypeptide 11, smooth muscle 0.12
Acrbp Proacrosin binding protein 0.12
Apof Apolipoprotein F 0.12
Nkx2-6 NK2 transcription factor related, locus 6 (Drosophila) 0.12
Hhip Hedgehog-interacting protein 0.12
Egf Epidermal growth factor 0.12
Upb1 Ureidopropionase, β 0.13
Prlr Prolactin receptor 0.13
Spc25 SPC25, NDC80 kinetochore complex component,
homolog (S. cerevisiae)
0.13
Nkx3-1 NK-3 transcription factor, locus 1 (Drosophila) 0.13
Hpgd Hydroxyprostaglandin dehydrogenase 15 (NAD) 0.13
Prlr Prolactin receptor 0.14
Table W4. (continued )
Gene Symbol Full Name Fold Expression
Gpr165 G protein–coupled receptor 165 0.14
Cbs Cystathionine β-synthase 0.14
Slc30a10 Solute carrier family 30, member 10 0.14
Bmpr1b Bone morphogenetic protein receptor, type 1B 0.14
Fcgbp Fc fragment of IgG binding protein 0.15
Fam38b2 Family with sequence similarity 38, member B2 0.15
Srd5a2 Steroid 5 α-reductase 2 0.15
Fam38b Family with sequence similarity 38, member B 0.15
Cdh8 Cadherin 8 0.15
Spink11 Serine peptidase inhibitor, Kazal type 11 0.16
Gabra4 γ-Aminobutyric acid (GABA) A receptor, subunit α 4 0.16
Abca5 ATP-binding cassette, subfamily A (ABC1), member 5 0.16
Pdzk1 PDZ domain containing 1 0.16
Slc30a2 Solute carrier family 30 (zinc transporter), member 2 0.16
Acvr1c Activin A receptor, type IC 0.17
H2-Q10 Histocompatibility 2, Q region locus 10 0.17
Fah Fumarylacetoacetate hydrolase 0.17
Bhlha15 Basic helix-loop-helix family, member a15 0.17
Slc26a4 Solute carrier family 26, member 4 0.17
Cckar Cholecystokinin A receptor 0.17
Cnn1 Calponin 1 0.18
Wif1 Wnt inhibitory factor 1 0.18
Ggt1 γ-Glutamyltransferase 1 0.18
Cyp2j13 Cytochrome P450, family 2, subfamily j, polypeptide 13 0.18
Slc5a3 Solute carrier family 5 (inositol transporters), member 3 0.18
Otud7a OTU domain containing 7A 0.18
Gm1574 Predicted gene 1574 0.19
Defb50 Defensin β50 0.19
Slc18a1 Solute carrier family 18 (vesicular monoamine), member 1 0.20
Chn2 Chimerin (chimaerin) 2 0.20
Tmem45a Transmembrane protein 45a 0.20
Man1a Mannosidase 1, α 0.20
Spink8 Serine peptidase inhibitor, Kazal type 8 0.20
Glb1l3 Galactosidase, β1 like 3 0.20
5430419D17Rik RIKEN cDNA 5430419D17 gene 0.21
9130230L23Rik RIKEN cDNA 9130230L23 gene 0.21
Fam115c Family with sequence similarity 115, member C 0.21
Myl9 Myosin, light polypeptide 9, regulatory 0.21
Rab39b RAB39B, member RAS oncogene family 0.21
Ms4a5 Membrane-spanning 4 domains, subfamily A, member 5 0.22
Gnmt Glycine N -methyltransferase 0.22
P2rx1 Purinergic receptor P2X, ligand-gated ion channel, 1 0.22
Doc2b Double C2, β 0.22
BC005685 cDNA sequence BC005685 0.22
Bmp7 Bone morphogenetic protein 7 0.22
BC005685 cDNA sequence BC005685 0.22
Upk1a Uroplakin 1A 0.22
Nxf7 Nuclear RNA export factor 7 0.22
Rnase1 Ribonuclease, RNase A family, 1 (pancreatic) 0.23
BC005685 cDNA sequence BC005685 0.23
Ndrg2 N-myc downstream regulated gene 2 0.23
Slco4c1 Solute carrier organic anion transporter family, member 4C1 0.23
Gpr110 G protein–coupled receptor 110 0.23
Slc22a1 Solute carrier family 22 (organic cation transporter),
member 1
0.23
Proc Protein C 0.24
Acrv1 Acrosomal vesicle protein 1 0.24
Aldh6a1 Aldehyde dehydrogenase family 6, subfamily A1 0.25
Figure W4. Quantitative PCR analysis of NF-κB–dependent target genes in IKK2ca(ca) lateral prostates compared with wild-type
(12 months; n = 5 per group). Error bars, SEM.
Figure W5. Expression of epithelial and stromal markers in epithelial and stromal cell lines. (A) Colored image of cytokeratin 14 (CK14)
staining of indicated epithelial cell lines in culture. Green indicates CK14 signal; blue, Hoechst signal. Scale bars, 50 μm. (B) Expression
profile of epithelial and stromal cell lines. The mRNA expression was determined by quantitative RT-PCR. (C) Expression of CXCL10
mRNA in the stromal cell line (str) on treatment with TNF (10 ng/ml). Ctrl indicates control cells (untreated). (D) Western blot showing
degradation of IκBα in transgenic cells, indicating IKK2 activity.
